Irinotecan in the treatment of gastric cancer

Annals of Oncology

Volumn 14, Issue SUPPL. 2, 2003, Pages

  Bugat, R ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL;

ADVANCED CANCER; ANOREXIA; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FEBRILE NEUTROPENIA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; REFERENCE VALUE; STANDARD; STOMACH CANCER; SURVIVAL TIME; VOMITING;

EID: 0038298072     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg727     Document Type: Article

References (20)

1. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993: 72: 37-41.
2. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-591.
3. Ohtsu A, Yoshida S, Miyata Y, Shimada Y. Recent advances in chemotherapy for advanced gastric cancer: from the standpoint of survival advantages. Gan To Kagaku Ryoho 1995; 22: 444-450.
4. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168.
5. Wils JA, Klein HO, Wagener DJT et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 927-931.
6. Kelsen D, Atiq OT, Saltz L et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10: 541-548.
7. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
8. Lacave AJ, Baron FJ, Anton LM et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991; 2: 751-754.
9. Anonymous. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). Anticancer Res 1992; 12: 1983-1988.
10. Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
11. Rougier P, Ducreux M, Mahjoubi M et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 1994; 30A: 1263-1269.
12. Köhne CH, Wils JA, Wilke HJ. Developments in the treatment of gastric cancer in Europe. Oncology (Huntingt) 2000; 14 (12 Suppl 14): 22-25.
13. Weitzen R, Ghodsizadeh A, Brenner H, Tichler T. Gastric carcinoma: continuous infusion 5-fluorouracil plus cisplatinum: dose intensification study. Eur J Cancer 1993; 29A (Suppl 6): S 104 (Abstr 560).
14. Futatsuki K, Wakui A, Nakao I et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994; 21: 1033-1038.
15. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17: 319-323.
16. Pozzo C, Bugat R, Peschel C et al. Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: Final results of a randomised phase II study. Proc Am Soc Clin Oncol 2001; 20: 134 (Abstr 531).
17. Ohtsu A, Boku N, Nagashima F et al. A phase I/II study of S-1 Plus cisplatin in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2001; 20: 165a (Abstr 656).
18. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530.
19. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
20. Valle JW. Adjuvant therapy for gastric cancer-has the standard changed? Br J Cancer 2001; 84: 875-877.